Ahmed Sawas, MD

Ahmed Sawas, MD is an Instructor of Clinical Medicine in the Department of Medicine, in the Center of Lymphoid Malignancies with an appointment to the Division of Hematology/Oncology and the Division of Experimental Therapeutics at the Columbia University College of Physicians and Surgeons and the New York-Presbyterian Hospital in New York City.

Dr. Sawas completed his pharmacology degree from Stony Brook University and received his medical degree from the State University of New York - Health Science Center at Brooklyn, College of Medicine in New York. He completed his internship and residency in internal medicine at the St. Vincent’s Catholic Medical Center/ New York Medical College. Dr. Sawas completed his fellowship in hematology and medical oncology at the New York University Medical Center. His research interests are focused on the development of novel therapies for lymphoma, as well as prognostic and predictive biomarkers of early response. Dr. Sawas serves as the principal investigator on many clinical trials and has authored or coauthored many publications and abstracts in peer reviewed journals on the diagnosis and treatment of lymphoma.

Additionally, Dr. Sawas is focused on the development of Magnetic Resonance Spectroscopy technology as a clinical tool. This is a promising non-invasive technology that allows ex-vivo evaluation of tumors before and during treatment. This technology can be used for both the clinical and research arena in an effort to develop prognostic factors and potential biomarkers of early response to therapy. Because of the technology’s ability to evaluate response on the molecular level, it would allow for the detection of response as early as the first cycle of chemotherapy. This would allow for individualization of therapy in the clinical setting, allowing patients to continue on therapies that are beneficial, while affording an opportunity at timely change of therapies that are sub-optimal.  In the developmental therapeutic setting, it would allow for the identification of active targets as well as limit clinical trial subjects’ exposure to ineffective and toxic agents.

Dr. Sawas is a member of the American Society of Hematology and the American Society of Clinical Oncology. He is focused on treating patients with lymphoma, myeloma, and other benign and malignant hematological disorders.